Navigation Links
Unigene to Present at TIDES 2012
Date:5/21/2012

BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at the TIDES 2012 conference for the oligonucleotide and peptide industry, being held at the Mandalay Bay Resort and Casino in Las Vegas, NV.

TIDES 2012 is the premier conference focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the applications and alternate delivery routes of peptide therapeutics.

Target Peptide Optimization and Recombinant Manufacturing of an Orally Delivered Peptide for the Treatment of Obesity

Spotlight Presentation – Emerging Technologies Showcase – Peptides

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, May 22, 2012 at 4:30 p.m. PDT
  • Focus: Development and oral delivery of a potent lead compound for the treatment of obesity  using Unigene's Peptelligence™ technology

Alternative Delivery Platforms for Oligonucleotide and Peptide Therapeutics

Strategy Discussion Forum

  • Panelist: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Wednesday, May 23 at 4:00 p.m. PDT
  • Focus: The advantages/disadvantages of alternative delivery platforms for oligonucleotide and peptide therapeutics and their acceptability to physicians, patients and health providers

"TIDES 2012 is an ideal forum for showcasing advancements in peptide therapeutics, including Unigene's oral peptide delivery technology which we have branded as Peptelligence™," said Dr. Mehta. "Without question, the oral delivery of peptide therapeutics is the most significant recent advancement in the peptide space as it offers the opportunity to redefine the treatment regimen and increase the market potential for numerous debilitating, chronic conditions.  Unigene is at the forefront of this paradigm shift, making TIDES 2012 an extremely valuable scientific and business development event for building awareness among companies and institutions that are developing next-generation peptide compounds and looking for new ways to expand existing peptide franchises."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
2. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
3. Unigene Reports Third Quarter 2011 Financial Results
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
7. Unigene Provides 2012 Business Outlook
8. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
9. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
10. Unigene to Present at IBCs 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
11. Unigene Appoints David Moskowitz as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... gab heute den Abschluss eines Kooperationsvertrags mit ... umfassender Lösungen in den Bereichen Next-Generation-Sequencing (NGS), ... QGEN ; Frankfurt Prime Standard: QIA) gab ... Genomics für die Entwicklung und Förderung umfassender ...
(Date:2/9/2016)... WORCESTER, Mass. , Feb. 9, 2016   ... earned The Joint Commission,s Gold Seal of Approval ® ... continuous compliance with its performance standards. The Gold Seal ... that reflects an organization,s commitment to providing safe and ... --> AllCare Plus Pharmacy underwent a rigorous on-site ...
(Date:2/9/2016)... The leader in accelerated orthodontics, OrthoAccel ® ... the recipient of the 2015 Townie Choice Award in ... medical device that speeds up orthodontic tooth movement by ... associated with treatment, AcceleDent was selected by orthodontists from ... Orthotown survey of the most reliable and reputable ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s (BPF) ... from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent MIT ... of an intact rabbit brain for extremely long-term storage using a combination of ...
(Date:2/8/2016)... ... 08, 2016 , ... Coast Dental has a new way to help parents ... and family dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February ... to Target at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , ... bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. ... up to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... IN metro area, has selected the latest beneficiary of their ongoing community enrichment ... to preventing bullying in area schools. Donations are now being accepted at: ...
Breaking Medicine News(10 mins):